Evidence-Based Complementary and Alternative Medicine / 2019 / Article / Tab 1 / Review Article
Kangai Injection, a Traditional Chinese Medicine, Improves Efficacy and Reduces Toxicity of Chemotherapy in Advanced Colorectal Cancer Patients: A Systematic Review and Meta-Analysis Table 1 Notes. E/C: experiment group and control group. F/M: female and male. N: not mentioned. ①: tumor response. ②: KPS. ③: nausea and vomiting. ④: diarrhea. ⑤: leukopenia. ⑥: thrombocytopenia. ⑦: liver dysfunction. ⑧: renal dysfunction. ⑨: neurotoxicity. ⑩: immune function. ⑪: survival time.
Study ID Sample size (E/C) Gender (F/M) Median age(E/C) Study design(E/C) Intervention KAI dosage (ml/day) Outcomes E C Cai 2015 [25 ] 45/45 49/41 50.24±2.4 Parallel-group FOLFIRI+KAI FOLFIRI 40 ①③④⑥⑦⑧ Chen 2008 [26 ] 26/26 24/28 59 Parallel-group FOLFOX4+KAI FOLFOX4 60 ①②③④⑤⑦⑧⑨ Chen 2016 [27 ] 46/46 34/58 61.2±11.7/62.1±11.4 Parallel-group FOLFOX4+KAI FOLFOX4 40 ①③④⑤ Ding 2012 [28 ] 32/32 25/39 54/53 Parallel-group FOLFOX4+KAI FOLFOX4 40 ①③④⑤⑥ Ding 2017 [29 ] 32/30 24/38 60/58 Parallel-group XELOX+KAI XELOX 40 ①②⑪ Guo 2015 [30 ] 50/50 45/55 58.2±1.2/58.4±2.6 Parallel-group FOLFOX4+KAI FOLFOX4 60 ①③④⑤⑦⑨ Guo 2016 [31 ] 46/46 41/51 59.7±1.5/59.9±1.2 Parallel-group FOLFOX4+KAI FOLFOX4 50 ③⑥ Han 2010 [32 ] 60/60 45/75 52/51 Parallel-group FOLFOX+KAI FOLFOX 40 ②③④⑤⑥⑨ Jiang 2011[33 ] 30/30 18/42 52.7/54.3 Parallel-group FOLFIRI+KAI FOLFIRI 40 ①②③⑤ Lei 2011 [34 ] 30/30 25/35 N Parallel-group FOLFOX4+KAI FOLFOX4 50 ②③④⑤⑥⑨ Li 2008 [35 ] 87/61 65/83 55 Parallel-group 5FU+CF+KAI 5FU+CF 40 ①②③ Li 2014 [36 ] 48/49 42/55 58.9±1.58/59.2±1.62 Parallel-group FOLFIRI+KAI FOLFIRI 40-60 ①②③④⑤⑥⑦⑧⑩ Li 2015 [37 ] 45/48 41/52 57.13±7.05/56.72±7.24 Parallel-group XELOX+KAI XELOX 40 ①⑪ Liang 2015[38 ] 31/31 24/38 53.8±6.4 Parallel-group FOLFOX+KAI FOLFOX 40 ①②⑦⑧ Liu 2010[39 ] 46/40 32/54 65 Parallel-group FOLFOX4+KAI FOLFOX4 60 ①②③⑤⑨ Ma 2016[40 ] 30/30 18/42 55±2.5 Parallel-group mFOLFOX6+KAI mFOLFOX6 40 ②③④⑦⑧ Qiao 2015[41 ] 25/25 17/33 54.4/56.2 Parallel-group FOLFOX+KAI FOLFOX 40 ①②⑤⑦⑧⑨ Qiu 2011[42 ] 21/22 16/27 52.7/56.9 Parallel-group FOLFOX4+KAI FOLFOX4 40 ①②③⑤ Ruan 2014[43 ] 33/34 34/33 N Parallel-group XELOX+KAI XELOX 40 ①②③⑤⑥⑦ Wang 2016[44 ] 50/50 46/54 56.4±4.9/56.8±4.6 Parallel-group FOLFOX+KAI FOLFOX 50 ①②⑤⑥⑦⑨ Xiao 2008 [45 ] 51/109 48/112 56/53.5 Parallel-group FOLFOX+KAI FOLFOX 40 ②③⑨⑪ Xiao 2017 [46 ] 26/24 26/24 55 Parallel-group mFOLFOX6+KAI mFOLFOX6 50 ②⑩ Xu 2018 [47 ] 68/68 63/73 56.5/57 Parallel-group FOLFOX+KAI FOLFOX 40 ①⑩⑪ Yang 2007[48 ] 24/24 18/30 56 Parallel-group FOLFOX+KAI FOLFOX 50 ①②⑤ Yang 2016[49 ] 41/41 44/38 71 Parallel-group FOLFOX4+KAI FOLFOX4 40 ②⑩ Yu 2018[50 ] 50/50 33/67 55.4±5.8/54.6±6.1 Parallel-group FOLFOX+KAI FOLFOX 60 ①⑨⑩ Zhang 2011[51 ] 22/23 15/30 42-71/45-73 Parallel-group L-OHP+5FU+KAI L-OHP+5FU 40 ①② Zhou 2011[52 ] 30/30 42/19 60.0±1.5/61.0±1.0 Parallel-group FOLFOX+KAI FOLFOX 60 ①②⑤⑥⑦⑨⑪
